| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1299 | |
| Phytochemical name or plant extracts | Nexrutine | |
| PMID | 24206214 | |
| Literature evidence | Based on these findings, we propose that Nexrutine may provide a novel approach for protection against breast cancer. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Herbal extract | |
| Source of phytochemicals or plant Extracts | Phellodendron amurense | |
| Geographical availability | Amur, China North-Central, China Southeast, Inner Mongolia, Japan, Khabarovsk, Korea, Kuril Is., Manchuria, Primorye, Sakhalin, Taiwan, Uzbekistan, Vietnam | |
| Plant parts | Bark | |
| Other cancers | Breast cancer, Prostate cancer | |
| Target gene or protein | CDK2, p21, p27, Cyclin D1, PGE2 synthase (mPGES), PPAR? | |
| Gene or Protein evidence | Nexrutine decreased cell survival and induced a G1 cell cycle arrest in SkBr3 and MDA-MB 231 cells, which were associated with reduced protein expression of Cyclin D1 and cdk2 along with increased protein expression of p21 and p27. The antiinflammatory effects of Nexrutine were evident with decreased prostaglandin (PG)E2 production, protein expression of microsomal PGE2 synthase (mPGES), and PPAR?. | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | The growth-inhibitory effect of Nexrutine was associated with apoptosis in SkBr3 cells and autophagy in MDA-MB231 cells. Based on these findings, we propose that Nexrutine may provide a novel approach for protection against breast cancer. | |
| Cell line/ mice model | SKBR-3, MDA-MB 231 | |
| Additional information | NA | |
| PubChem ID | NA | |
| Additional PMIDs | 34386623 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:774774-1 | |
| Safety | NA |